[
  {
    "ts": null,
    "headline": "Incyte: Wall Street Underestimates Strength Of Ruxolitinib Portfolio",
    "summary": "Incyteâs share price soars, driven by strong Q2 2025 results, Niktimvoâs impressive sales, and raised guidance for Jakafi. Find out why INCY stock is a buy.",
    "url": "https://finnhub.io/api/news?id=5fdc2794ca25a235e89a1c36a1a56999a66e7c430e27b22b414aa35f1746c4c8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756546242,
      "headline": "Incyte: Wall Street Underestimates Strength Of Ruxolitinib Portfolio",
      "id": 136580696,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1329696857/image_1329696857.jpg?io=getty-c-w1536",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "Incyteâs share price soars, driven by strong Q2 2025 results, Niktimvoâs impressive sales, and raised guidance for Jakafi. Find out why INCY stock is a buy.",
      "url": "https://finnhub.io/api/news?id=5fdc2794ca25a235e89a1c36a1a56999a66e7c430e27b22b414aa35f1746c4c8"
    }
  }
]